ANI Pharmaceuticals Inc (ANIP) Shares Sold by Thrivent Financial for Lutherans

Share on StockTwits

Thrivent Financial for Lutherans lessened its position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 7.9% during the 4th quarter, Holdings Channel reports. The firm owned 5,851 shares of the specialty pharmaceutical company’s stock after selling 500 shares during the quarter. Thrivent Financial for Lutherans’ holdings in ANI Pharmaceuticals were worth $263,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. South Dakota Investment Council purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth about $45,000. Municipal Employees Retirement System of Michigan purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth about $115,000. Metropolitan Life Insurance Co. NY raised its holdings in ANI Pharmaceuticals by 324.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 2,872 shares of the specialty pharmaceutical company’s stock worth $129,000 after purchasing an additional 2,195 shares during the period. Oregon Public Employees Retirement Fund acquired a new position in ANI Pharmaceuticals in the 4th quarter worth about $142,000. Finally, Paloma Partners Management Co acquired a new position in ANI Pharmaceuticals in the 3rd quarter worth about $239,000. Institutional investors and hedge funds own 59.75% of the company’s stock.

In other ANI Pharmaceuticals news, insider Arthur Przybyl sold 27,625 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $63.53, for a total transaction of $1,755,016.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Robert W. Schrepfer sold 4,651 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $64.43, for a total value of $299,663.93. Following the transaction, the senior vice president now directly owns 53,484 shares of the company’s stock, valued at approximately $3,445,974.12. The disclosure for this sale can be found here. 33.10% of the stock is owned by corporate insiders.

A number of equities analysts recently weighed in on the company. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price target for the company in a report on Thursday, March 28th. Raymond James set a $73.00 price target on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 28th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 19th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Finally, ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $73.25.

NASDAQ ANIP opened at $68.60 on Wednesday. The stock has a market capitalization of $811.20 million, a P/E ratio of 14.88 and a beta of 2.42. ANI Pharmaceuticals Inc has a twelve month low of $36.92 and a twelve month high of $72.81. The company has a quick ratio of 0.68, a current ratio of 0.92 and a debt-to-equity ratio of 0.34.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.08. The company had revenue of $57.12 million during the quarter, compared to analysts’ expectations of $53.48 million. ANI Pharmaceuticals had a return on equity of 28.84% and a net margin of 7.69%. ANI Pharmaceuticals’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.08 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals Inc will post 5.97 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “ANI Pharmaceuticals Inc (ANIP) Shares Sold by Thrivent Financial for Lutherans” was posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2019/04/17/ani-pharmaceuticals-inc-anip-shares-sold-by-thrivent-financial-for-lutherans/3359479.html.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Featured Article: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.